A Study to Determine the Safety and Efficacy of Once Daily Raltegravir Compared to Twice Daily Raltegravir (MK-0518-071)

This study has been terminated.

( Primary efficacy analysis at Week 48 did not demonstrate non-inferiority of raltegravir 800 mg once daily versus raltegravir 400 mg twice daily )

Study NCT00745823 Information provided by Merck

First Received: September 2, 2008 Last Updated: September 29, 2011 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study has been terminated.
Study Completion Date:	May 2011
Primary Completion Date:	October 2010 (Final data collection date for primary outcome measure)
Extension Request:	Submission Date: September 29, 2011 Status: Submitted